| Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit ML Mohler, CE Bohl, A Jones, CC Coss, R Narayanan, Y He, DJ Hwang, ... Journal of medicinal chemistry 52 (12), 3597-3617, 2009 | 232 | 2009 |
| Recent and emerging anti‐diabetes targets ML Mohler, Y He, Z Wu, DJ Hwang, DD Miller Medicinal research reviews 29 (1), 125-195, 2009 | 134 | 2009 |
| A selective androgen receptor modulator for hormonal male contraception J Chen, DJ Hwang, CE Bohl, DD Miller, JT Dalton Journal of Pharmacology and Experimental Therapeutics 312 (2), 546-553, 2005 | 115 | 2005 |
| The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides is a major structural determinant of in vivo disposition and … J Kim, D Wu, DJ Hwang, DD Miller, JT Dalton Journal of Pharmacology and Experimental Therapeutics 315 (1), 230-239, 2005 | 105 | 2005 |
| Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy KE Arnst, S Banerjee, H Chen, S Deng, DJ Hwang, W Li, DD Miller Medicinal research reviews 39 (4), 1398-1426, 2019 | 94 | 2019 |
| A potent, metabolically stable tubulin inhibitor targets the colchicine binding site and overcomes taxane resistance KE Arnst, Y Wang, DJ Hwang, Y Xue, T Costello, D Hamilton, Q Chen, ... Cancer research 78 (1), 265-277, 2018 | 94 | 2018 |
| HIV-1 integrase inhibitory phenylpropanoid glycosides fromClerodendron trichotomum HJ Kim, ER Woo, CG Shin, DJ Hwang, H Park, YS Lee Archives of pharmacal research 24, 286-291, 2001 | 86 | 2001 |
| Dicaffeoyl-or digalloyl pyrrolidine and furan derivatives as HIV integrase inhibitors DJ Hwang, SN Kim, JH Choi, YS Lee Bioorganic & medicinal chemistry 9 (6), 1429-1437, 2001 | 80 | 2001 |
| Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy A Jones, DJ Hwang, R Narayanan, DD Miller, JT Dalton Endocrinology 151 (8), 3706-3719, 2010 | 75 | 2010 |
| Multi-substitued selective androgen receptor modulators and methods of use thereof JT Dalton, DD Miller, MS Steiner, KA Veverka, DJ Hwang, J Chen US Patent 7,803,970, 2010 | 69 | 2010 |
| Structural optimization of indole derivatives acting at colchicine binding site as potential anticancer agents DJ Hwang, J Wang, W Li, DD Miller ACS medicinal chemistry letters 6 (9), 993-997, 2015 | 65 | 2015 |
| Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer S Ponnusamy, CC Coss, T Thiyagarajan, K Watts, DJ Hwang, Y He, ... Cancer research 77 (22), 6282-6298, 2017 | 64 | 2017 |
| Structural and functional evidence for testosterone activation of GPRC6A in peripheral tissues M Pi, K Kapoor, Y Wu, R Ye, SE Senogles, SK Nishimoto, DJ Hwang, ... Molecular endocrinology 29 (12), 1759-1773, 2015 | 61 | 2015 |
| Irreversible selective androgen receptor modulators and methods of use thereof J Dalton, D Miller, M Steiner, K Veverka, L Kirkovsky, A Mukherjee, ... US Patent App. 10/371,209, 2004 | 61 | 2004 |
| Preclinical Characterization of a (S)-N-(4-Cyano-3-Trifluoromethyl-Phenyl)-3-(3-Fluoro, 4-Chlorophenoxy)-2-Hydroxy-2-Methyl-Propanamide: A Selective … A Jones, J Chen, DJ Hwang, DD Miller, JT Dalton Endocrinology 150 (1), 385-395, 2009 | 55 | 2009 |
| Arylisothiocyanato selective androgen receptor modulators (SARMs) for prostate cancer DJ Hwang, J Yang, H Xu, IM Rakov, ML Mohler, JT Dalton, DD Miller Bioorganic & medicinal chemistry 14 (19), 6525-6538, 2006 | 51 | 2006 |
| Current advances of tubulin inhibitors in nanoparticle drug delivery and vascular disruption/angiogenesis S Banerjee, DJ Hwang, W Li, DD Miller Molecules 21 (11), 1468, 2016 | 49 | 2016 |
| Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators CE Bohl, Z Wu, J Chen, ML Mohler, J Yang, DJ Hwang, S Mustafa, ... Bioorganic & medicinal chemistry letters 18 (20), 5567-5570, 2008 | 48 | 2008 |
| Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates ML Mohler, VA Nair, DJ Hwang, IM Rakov, R Patil, DD Miller Expert Opinion on Therapeutic Patents 15 (11), 1565-1585, 2005 | 47 | 2005 |
| Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate CancerA Novel AR Degrader for the Treatment of … S Ponnusamy, Y He, DJ Hwang, T Thiyagarajan, R Houtman, ... Clinical Cancer Research 25 (22), 6764-6780, 2019 | 43 | 2019 |
